CAS: 1592-23-0; Calcium Stearate

上下游产品

CAS号57-11-4 硬脂酸

专利信息

专利号:US-2021284618-A1
优先权日:2016-08-12
标 题 :Furanochalcones as inhibitors of cyp1a1, cyp1a2 and cyp1b1 for cancer chemoprevention
发明人：BHARATE SANDIP BIBISHAN; SHARMA RAJNI; JOSHI PRASHANT; VISHWAKARMA RAM; CHAUDHURI BHABATOSH
权利人:COUNCIL SCIENT IND RES; DE MONTFORT UNIV
摘要:The present invention relates to the furanochalcone class of compounds of general formula A. The present invention particularly relates to the synthesis of furanochalcones and their CYP1A1, CYP1A2 and CYP1B1 inhibitory activity. In addition, the invention relates to the prevention or treatment of cancer caused by polyaromatic hydrocarbons (PAHs), 4-nitroquinoline-1-oxide, and N-nitroso-N-methylurea, heterocyclic amines, estrogen and 17β-estradiol, resulting from the inhibition of CYP1A1, CYP1A2 and CYP1B1 enzymes.

专利号:WO-9713503-A1
优先权日:1995-10-13
标 题:Synthesis of drug nanoparticles by spray drying
发明人：SELVARAJ ULAGARAJ; MESSING GARY L
权利人:PENN STATE RES FOUND; SELVARAJ ULAGARAJ; MESSING GARY L
摘要:The present invention relates to a method for synthesizing nanoparticles comprising combining an agent and a matrix to form a composite mixture, and spray drying the composite mixture, wherein the nanoparticles are less than about 5000 nm. Suitable agents that can be formulated into nanoparticle in the context of the present invention include therapeutic and diagnostic agents, cosmetic, dye, photographic, food, pesticide agents, among others.

专利号:WO-2023197278-A1
优先权日:2022-04-15
标题 :Solvent-free synthesis method for sucrose ester having high monoester content
发明人：XU SHENG; LIANG ZHENMING; Min Juping; SHAO LEI; XU HUAIYI
权利人:GUANGZHOU CARDLO BIOCHEMICAL TECH CO LTD
摘要:Disclosed is a solvent-free synthesis method for a sucrose ester having high monoester content. The method comprises the following steps: (1) mixing sucrose, a higher fatty acid ester, and a higher fatty acid salt, and preheating at 70-90°C to obtain a mixture; and (2) mixing the mixture and a catalyst, and reacting at 120-140°C to obtain the sucrose ester. According to the synthesis method involved in the present application, a solvent-free ester transesterification method is used, the sucrose, the higher fatty acid ester, the higher fatty acid salt, and the catalyst turn into a co-molten state in a certain ratio at a high temperature, and the sucrose ester is catalytically synthesized under reaction conditions facilitating kinetics. According to the synthesis method, the use of a solvent is avoided, the problem of toxicity is solved, a product can meet medical and edible standards, sucrose monoester content in the product is high, and the color of the prepared product is good; the synthesis method has simple steps, facilitates industrial production, and has important application value.

专利号:WO-2020244507-A1
优先权日:2019-06-06
标题:Use of nicotinamide mononucleotide and/or nicotinamide mononucleotide salt
发明人：CHEN JIANSHENG
权利人:HOBOOMLIFE BIO TECH SHENZHEN CO LTD
摘要:The present invention relates to the field of medicament and health food research and development, and in particular to use of a nicotinamide mononucleotide and/or a nicotinamide mononucleotide salt. Provided is use of a nicotinamide mononucleotide or a nicotinamide mononucleotide salt in preparation of anti-allergic medicaments and/or anti-allergic health care products. In the technical solution, using the nicotinamide mononucleotide or the nicotinamide mononucleotide salt can induce Treg cells to secrete immunosuppressive cytokines IL10, TGF-β and the like, so as to inhibit the immune response of TH2, blood basicytes and tissue mast cells, reduce sIgE synthesis, increase sIgG and sIgA synthesis at the same time, and finally alleviate allergic symptoms. Further, it can be found through experiments that after using the nicotinamide mononucleotide and/or the nicotinamide mononucleotide salt, there are fewer adverse reactions and allergy recurrence rate is reduced. Provided is use of the nicotinamide mononucleotide and/or the nicotinamide mononucleotide salt for solving the technical defects in the prior art that antiallergic medicament have some adverse reactions and need to be used repeatedly and allergies tend to recur.

专利号:US-RE49935-E
优先权日:2012-10-17
标 题:Crystalline polymorphs of benfotiamine, process for preparation and its use thereof
发明人：ZHONG CHUNJIU; HE YINHUA; MEI XUEFENG; ZHANG HUAN
权利人:SHANGHAI RAISING PHARMACEUTICAL CO LTD
摘要:The present invention is directed to crystalline polymorphs of benfotiamine, its methods of preparation and its use thereof. Five crystalline polymorphs of benfotiamine are designated as crystalline forms A, B, C, D and E, and may be distinguished by their respective patterns of X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy, moreover by their diverse preparing process. The crystalline polymorphs of the present invention are useful as they act in treating Vitamin B1 deficiency, metabolic disorders, mental illness and disorders, diabetes complications, neurodegerative diseases. Further the present invention is a process for preparing and transforming diverse crystalline form of benfotiamine through different synthesis routes and varied solvents and combinations. The crystalline polymorphs of the present invention are basically pure. The present invention not only provides new crystalline forms of benfotiamine, but also provides its new solvates, especially hydrates.

专利号:US-7582653-B2
优先权日:2003-03-31
标 题 :Mercaptophenyl naphthyl methane compounds and synthesis thereof
权利人:COUNCIL SCIENT IND RES
摘要:Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.